NCT06388122View on ClinicalTrials.gov

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

June 15, 2031

Study Completion Date

June 15, 2031

Conditions
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06388122 - DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter